• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

No significant differences between medications for episodic migraine prophylaxis

byAdrian WongandThomas Su
February 3, 2025
in Neurology, Pediatrics Classics, Pharma, Restricted
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this systematic review and meta-analysis, there were no significant differences between various pharmacologic treatments for preventing episodic migraine in adults.

2. While calcitonin gene-related peptide antagonist monoclonal antibodies appeared to be more efficacious and tolerable than other drug classes, the evidence was of lower certainty.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Many pharmacologic options exist for treating episodic migraine. Although it has been established that these treatments are effective compared with placebo, there is still a lack of research comparing these treatments with one another. This systematic review aimed to evaluate the relative effectiveness and harms of each treatment. In terms of migraine frequency, moderate- and low-certainty evidence demonstrated no significant differences between beta-blockers and valproate, between calcitonin gene-related peptide antagonist monoclonal antibodies (CGRP-mAbs) and gepants, or between amitriptyline and topiramate. Venlafaxine was associated with shorter headache duration compared with amitriptyline, but no significant difference in duration was found between the beta-blocker propranolol and valproate. The CGRP-mAb erenumab was associated with reduced acute medication intake days at higher dosages, but pairwise comparisons showed a lack of significant evidence that any drug class was more effective in this criterion than another. CGRP-mAbs were also associated with less migraine-related disability and an improvement in quality of life compared with gepants. CGRP-mAbs and beta-blockers were both associated with fewer treatment discontinuations compared with topiramate, while no differences were found in this regard between CGRP-mAbs and gepants or between angiotensin receptor blockers (ARBs) and beta-blockers. The generalizability of this study was limited by the lack of direct comparisons between treatments. Nevertheless, this study suggested that in general, no significant differences exist between pharmacologic treatments for preventing migraines.

Click to read the study in AIM

Relevant Reading: The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis

RELATED REPORTS

Commonly cited medication triggers may not increase risk of microscopic colitis among older adults

Levofloxacin shows limited efficacy in preventing multidrug-resistant tuberculosis

Patient values and preferences when considering migraine prevention options

In-Depth [systematic review and meta-analysis]: This study aimed to compare the effectiveness and harms of various pharmacologic treatments for episodic migraine prevention in adults. A total of 61 studies were selected, yielding a population that was 84% female and had a median age of 41 years. Participants suffered from migraine headaches at a median of every 7.8 days, and 53% of participants had previously used migraine prevention treatments. In terms of headache frequency, no significant differences were found between beta-blockers and valproate (mean difference [MD], -0.19 migraine days per month [95% CI, -1.56 to 1.18]), between CGRP-mAbs and gepants (MD, -0.40 migraine days per month [95% CI, -1.67 to 0.87]), between amitriptyline and combination topiramate and amitriptyline (MD, -0.28 migraine days per month [95% CI, -1.45 to 0.90]), or between topiramate and combination topiramate and amitriptyline (MD, -0.07 migraine days per month [95% CI, -1.24 to 1.11]). Low-certainty evidence suggested that venlafaxine was associated with shorter headache durations compared with amitriptyline (MD, -6.11 hours [95% CI, -9.53 to -2.69]). Propranolol was not significantly associated with changes in headache duration compared with valproate (MD, -1.64 hours [95% CI, -3.68 to 0.40]). Low-certainty evidence suggested that CGRP-mAbs were associated with less migraine-related disability (MD, -4.12 points [95% CI, -9.30 to 1.05]) and improved quality of life in the role function-restrictive domain (MD, 2.25 points [95% CI, -0.85 to 5.34]) compared with gepants. Regarding harms, low-certainty evidence indicated that CGRP-mAbs (risk difference [RD], -16.2% [95% CI, -18.4% to -12.8%]) and propranolol (RD, -15.7% [95% CI, -19.0% to -10.1%]) may result in fewer discontinuations compared with topiramate. Risk of medication discontinuation was similar between CGRP-mAbs and gepants (RD, -0.9% [95% CI, -1.7% to 3.1%]), and between ARBs and beta-blockers (RD, -1.3% [95% CI, -2.5% to 5.1%]). Overall, this study showed a general lack of significant differences in efficacy or harms between various migraine prevention treatments.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angiotensin receptor blocker (ARB)beta blockercalcitonin gene-related peptide (CGRP) receptor antagonistschronic migrainedisabilityProphylaxisvalproate
Previous Post

Blood pressure readings remain consistent in noisy and public settings

Next Post

Patient values and preferences when considering migraine prevention options

RelatedReports

Multiple opioid prescriptions associated with higher hospital admissions
Gastroenterology

Commonly cited medication triggers may not increase risk of microscopic colitis among older adults

July 4, 2025
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Infectious Disease

Levofloxacin shows limited efficacy in preventing multidrug-resistant tuberculosis

March 5, 2025
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Neurology

Patient values and preferences when considering migraine prevention options

February 3, 2025
Cardiology

Beta-blocker interruption not noninferior to continuation following myocardial infarction

November 21, 2024
Next Post
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Patient values and preferences when considering migraine prevention options

Paternal factors associated with short interpregnancy interval

Fresh embryo transfer may yield higher rates of success for women with low prognosis for in vitro fertilization

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard
  • AAV gene therapy shows durable benefit in hemophilia B
  • Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.